Caris Life Sciences Inc (CAI) posted 27% revenue growth to a record $275.4 million, returned to GAAP profitability, and lifted its 2026 revenue outlook to roughly $1.04 billion to $1.05 billion.
Caris Life Sciences (CAI) has drawn fresh attention after reporting third quarter 2026 earnings, with revenue of US$275.36 million and earnings of US$0.05 per share, alongside a higher full year revenue outlook. At a share price of US$33.22, Caris Life Sciences has posted a 30 day share price return of 21% and a 90 day share price return of 46.09%. The 1 year total shareholder return of 34.99% points to momentum that has been building rather than fading over time. Spot similar momentum and...
Caris stock is taking a breather after charging higher over just two months. Wait for the IPO stock to offer a new buy point.
Caris Life Sciences has surged off its May low near 14. The molecular research firm for drug companies might turn profitable this year.
Key TakeawaysSector Rally: Caris Life Sciences (CAI) stock jumped 9. 61% to close at $31 on Thursday, September 17, riding a Fed-driven market rally and a surge across AI-powered precision oncology peers.
Caris Life Sciences, Inc. (CAI) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Caris Life Sciences, Inc. (CAI) has an average rating of overweight and mean price target of $27.08,
Caris Life Sciences (CAI) is drawing fresh attention after announcing that its researchers will present seven lung cancer studies at the 2026 World Conference on Lung Cancer in Seoul this month. For investors, the World Conference presentations and August’s pancreatic cancer AI publication land against a mixed share price backdrop for Caris Life Sciences, with the stock down 28.06% on a 1 year total shareholder return basis but showing strong 90 day share price momentum of 55.33% and a 30 day...
Caris Life Sciences (NasdaqGS: CAI) announced plans to present seven major precision oncology studies at the IASLC 2026 World Conference on Lung Cancer. The company highlighted new data on molecular profiling and AI powered analysis for lung cancer care. Caris also published a validated AI driven method designed to help optimize first line pancreatic cancer treatment choices. For readers following how AI is reshaping cancer research and treatment, it can also be useful to look at other...
This is the newest page. Registered accounts read further back.